Recent Quotes (30 days)

You have no recent quotes
chg | %

Quidel Corporation  

(Public, NASDAQ:QDEL)   Watch this stock  
Find more results for QDEL
39.08
+0.08 (0.21%)
Nov 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.54 - 39.53
52 week 18.25 - 45.55
Open 39.01
Vol / Avg. 0.00/341,039.00
Mkt cap 1.33B
P/E     -
Div/yield     -
EPS -0.16
Shares 34.00M
Beta 1.20
Inst. own 95%
Feb 6, 2018
Q4 2017 Quidel Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 28, 2017
Quidel Corp at Piper Jaffray Healthcare Conference - 9:00AM EST - Add to calendar
Nov 1, 2017
Q3 2017 Quidel Corp Earnings Call - Webcast
Nov 1, 2017
Q3 2017 Quidel Corp Earnings Release
Sep 18, 2017
Quidel Corp Revised Agreement with Alere Inc M&A Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -10.86% -7.21%
Operating margin -4.98% -2.32%
EBITD margin - 9.64%
Return on average assets -5.46% -3.47%
Return on average equity -10.27% -6.59%
Employees 627 -
CDP Score - -

Address

12544 High Bluff Dr Ste 200
SAN DIEGO, CA 92130-3050
United States - Map
+1-858-5521100 (Phone)
+1-858-4534338 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women's health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

Officers and directors

Kenneth F. Buechler Ph.D. Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Douglas C. Bryant President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Randall J. Steward Chief Financial Officer
Age: 62
Bio & Compensation  - Reuters
Robert Joseph Bujarski J.D. Senior Vice President - Business Development, General Counsel and Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Michael D. Abney Jr. Senior Vice President - Distribution
Age: 81
Bio & Compensation  - Reuters
Werner Kroll Ph.D Senior Vice President,R&D
Age: 60
Bio & Compensation  - Reuters
Edward Keith Russell Senior Vice President - Global Commercial Operations
Age: 49
Bio & Compensation  - Reuters
Thomas D. Brown Independent Director
Age: 69
Bio & Compensation  - Reuters
Mary Lake Polan M.D. Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Jack W. Schuler Independent Director
Age: 76
Bio & Compensation  - Reuters